12:00 AM
 | 
Apr 26, 2010
 |  BioCentury  |  Emerging Company Profile

Cardio3: Showing heart

Cardio3 hopes for IPO to take autologous stem cell therapy to market for CHF

Treatments for heart failure and myocardial infarction generally address only the symptoms of the disease. Cardio3 BioSciences S.A. believes its stem cell-derived cardiopoietic cells can help repair damaged heart tissue, and says its challenge will be to get to market in order to show potential partners that the business model can make money.

Under a license from the Mayo Clinic, Cardio3 uses a cocktail of undisclosed cardiogenic factors to induce pluripotent stem cells to differentiate into cardiac progenitor cells.

The company's lead therapeutic is C-Cure, an autologous cell therapy for congestive heart failure (CHF) that is derived from mesenchymal stem cells removed from bone marrow. The cells are processed and expanded into cardiopoietic cells using the undisclosed factors and are then injected into the myocardium. There, the environment stimulates the cells to differentiate into cardiomyocytes.

According to co-founder and CEO Christian Homsy, unpublished data from mouse studies have shown two mechanisms by which C-Cure repairs damaged heart tissue: first, the cells engraft into the heart muscle, increasing the number of healthy cardiac cells. Second, C-Cure cells secrete growth factors that stimulate the repair...

Read the full 896 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >